PreveCeutical Medical (PREV) AI Stock Analysis

• Market Cap: C$11.74M
• Dividend Yield: N/A
• Average Volume (3M): 143.42K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.24
• Revenue Growth: N/A
• EPS Growth: -120.00%
• Country: CA
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 586,811,950
• 10 Day Avg. Volume: 276,937
• 30 Day Avg. Volume: 143,419
• PEG Ratio: 114.24
• Price to Book (P/B): -2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.02 ▲(20.00% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is driven down primarily by weak financial performance—no revenue, widening losses, cash burn—and a stressed balance sheet with negative equity and notable leverage. Technicals add downside pressure as the stock trades below key moving averages with negative MACD. Corporate events provide some offset via strategic restructuring and new financing, but they do not fully mitigate the underlying funding and execution risks.

Positive Factors

Focused R&D in pharmaceutical and cannabinoid therapeutics

The company’s explicit focus on pharmaceutical and therapeutic technologies, including cannabinoid delivery platforms and drug-development programs, provides a clear strategic niche. A sustained R&D focus in a specialized therapeutic area can yield durable IP, regulatory pathways, and differentiated products if programs advance.

Negative Factors

No revenue and widening operating losses

Absence of operating revenue alongside widening losses is a fundamental weakness: it indicates lack of commercial validation and forces reliance on financing. Persisting negative earnings means continued cash drain and raises execution risk over the next several months absent product or partnership commercialization.

PreveCeutical Medical Business Overview & Revenue Model

Company Description

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a canna...

Read more

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a canna...

How the Company Makes Money

PreveCeutical makes money primarily through the research and development of therapeutic products, which are then licensed or sold to pharmaceutical companies or healthcare providers. The company may also generate revenue through strategic partners...

Read more

PreveCeutical makes money primarily through the research and development of therapeutic products, which are then licensed or sold to pharmaceutical companies or healthcare providers. The company may also generate revenue through strategic partners...

PreveCeutical Medical Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-10.13K	-10.10K	-9.86K	-9.89K	-5.09K	-75.17K
EBITDA	-2.78M	-837.46K	-955.09K	-1.23M	-829.83K	-2.02M
Net Income	-3.08M	-1.17K	-1.27M	-1.48M	-1.73M	-3.80M
Balance Sheet
Total Assets	456.04K	225.66K	181.51K	189.14K	161.20K	302.45K
Cash, Cash Equivalents and Short-Term Investments	103.68K	59.14K	1.43K	5.62K	16.06K	156.44K
Total Debt	4.60M	4.46M	3.83M	3.23M	2.93M	3.01M
Total Liabilities	7.85M	6.86M	5.96M	4.82M	4.27M	3.91M
Stockholders Equity	-7.45M	-6.64M	-5.78M	-4.64M	-4.10M	-3.60M
Cash Flow
Free Cash Flow	-1.31M	-428.49K	-296.97K	-222.64K	-481.59K	61.94K
Operating Cash Flow	-1.25M	-426.69K	-296.97K	-222.64K	-426.39K	64.59K
Investing Cash Flow	-6.23K	-1.80K	0.00	850.00	-52.70K	-2.65K
Financing Cash Flow	1.39M	487.64K	293.62K	211.72K	136.75K	184.46K

PreveCeutical Medical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PREV.

PreveCeutical Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BETR	52 Neutral	C$9.11M	-6.03	19.14%	―	―	62.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDMA	49 Neutral	C$11.98M	-6.26	-78.88%	―	-72.51%	-170.13%
PREV	42 Neutral	C$11.74M	-5.25	21.59%	―	―	-120.00%
DOSE	42 Neutral	C$12.53M	-4.62	75.85%	―	95.76%	22.56%

PreveCeutical Medical Corporate Events